In addition, higher nuclear HER4 expression at day 21 was correlated with a poorer clinical response to trastuzumab monotherapy, including a higher tumour volume (r=0.859, p=0.023) and Ki67 level ratios (r=0.897, p=0.014) (Figure 7E). Here, ERBB4 is linked to neoplasm.